p95HER2–T cell bispecific antibody for breast cancer treatment
2018 · Science Translational Medicine · 76 citations
https://doi.org/10.1126/scitranslmed.aat1445
B
Beatriz Morancho
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
92
Papers
1.7K
Citations
18
h-index
21
i10-index
Beatriz Morancho is an academic researcher. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Telomeres, Telomerase, and Senescence. The author has an h-index of 18, co-authored 79 publications.
ORCID: 0000-0003-3369-8647Papers by this author
worksPatterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
2015 · PLoS ONE · 60 citations
https://doi.org/10.1371/journal.pone.0129876
Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy
2014 · JNCI Journal of the National Cancer Institute · 54 citations
https://doi.org/10.1093/jnci/dju291
Analysis of the transcriptional activity of endogenous NFAT5 in primary cells using transgenic NFAT-luciferase reporter mice
2008 · BMC Molecular Biology · 43 citations
https://doi.org/10.1186/1471-2199-9-13
Effect of Cellular Senescence on the Growth of HER2-Positive Breast Cancers
2015 · JNCI Journal of the National Cancer Institute · 42 citations
https://doi.org/10.1093/jnci/djv020
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
2022 · Cancer Research · 40 citations
https://doi.org/10.1158/0008-5472.can-22-0787
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat